Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
Carcinoma, Renal Cell
Axitinib shows clinical activity in patients with cytokine-refractory metastatic renal-cell cancer. Although 28 patients had grade 3 or grade 4 treatment-related adverse events, these adverse events were generally manageable and controlled by dose modification or supportive care, or both. Further studies are needed to confirm these findings.